Curability of patients with acute myeloid leukemia who did not undergo transplantation in first remission

Journal of Clinical Oncology

Volumn 31, Issue 10, 2013, Pages 1293-1301

  Burnett, Alan K ^a   Goldstone, Anthony ^b   Hills, Robert K ^a   Milligan, Donald ^d   Prentice, Archie ^c   Yin, John ^f   Wheatley, Keith ^e   Hunter, Ann ^g   Russell, Nigel ^h  

^a CARDIFF UNIVERSITY SCHOOL OF MEDICINE   (United Kingdom)

^b UNIVERSITY COLLEGE HOSPITAL   (United Kingdom)

^c ROYAL FREE HOSPITAL   (United Kingdom)

^d BIRMINGHAM HEARTLANDS HOSPITAL   (United Kingdom)

^e UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^f MANCHESTER ROYAL INFIRMARY   (United Kingdom)

^g LEICESTER ROYAL INFIRMARY   (United Kingdom)

^h NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; CYTARABINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ADVERSE OUTCOME; ALLOTRANSPLANTATION; ARTICLE; CANCER CHEMOTHERAPY; CYTOGENETICS; DEATH; FOLLOW UP; HIGH RISK PATIENT; HUMAN; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; MEDICAL DECISION MAKING; OVERALL SURVIVAL; PRIORITY JOURNAL; REDUCED INTENSITY CONDITIONING; SALVAGE THERAPY; UNRELATED DONORS; WILD TYPE;

ACUTE DISEASE; ADOLESCENT; ADULT; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LEUKEMIA, MYELOID; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MUTATION; NUCLEAR PROTEINS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RECURRENCE; REMISSION INDUCTION; RISK ASSESSMENT; RISK FACTORS; STEM CELL TRANSPLANTATION; TIME FACTORS; TRANSPLANTATION, HOMOLOGOUS; YOUNG ADULT;

EID: 84876087623     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.40.5977     Document Type: Article

References (31)

1. Grimwade D, Walker H, Harrison G, et al: The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): Analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood 98:1312-1320, 2001
2. Slovak ML, Kopecky KJ, Cassileth PA, et al: Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: A Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood 96:4075-4083, 2000
3. Byrd JC, Mrózek K, Dodge RK, et al: Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse and overall survival in adult patients with de novo acute myeloid leukemia: Results from Cancer and Leukemia Group B (CALGB 8461). Blood 100:4325-4336, 2002 (Pubitemid 35429670)
4. Döhner K, Döhner H: Molecular characterization of acute myeloid leukemia. Haematologica 93:976-982, 2008
5. Burnett AK, Goldstone AH, Stevens RM, et al: Randomised comparison of addition of autologous bone-marrowtransplantation to intensivechemotherapy for acute myeloid leukaemia in first remission: Results of MRC AML 10 trial. UK Medical Research Council Adult and Children's Leukaemia Working Parties. Lancet 351:700-708, 1998 (Pubitemid 28105339)
6. Zittoun RA, Mandelli F, Willemze R, et al: Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) Leukemia Cooperative Groups. N Engl J Med 332:217-223, 1995
7. Gupta V, Tallman MS, Weisdorf DJ: Allogeneic hematopoietic cell transplantation for adults with acute myeloid leukemia: Myths, controversies, and unknowns. Blood 117:2307-2318, 2011
8. Litzow MR, Tarima S, Pérez WS, et al: Allogeneic transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia. Blood 115:1850-1857, 2010
9. Cornelissen JJ, van Putten WL, Verdonck LF, et al: Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: Benefits for whom? Blood 109:3658-3666, 2007 (Pubitemid 46641712)
10. Koreth J, Schlenk R, Kopecky KJ, et al: Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: Systematic review and meta-analysis of prospective clinical trials. JAMA 301:2349-2361, 2009
11. Burnett AK, Hills RK, Milligan DW, et al: Attempts to optimize induction and consolidation treatment in acute myeloid leukemia: Results of the MRC AML12 trial. J Clin Oncol 28:586-595, 2010
12. Falini B, Mecucci C, Tiacci E, et al: Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med 352:254-266, 2005 (Pubitemid 40110814)
13. Fröhling S, Skelin S, Liebisch C, et al: Comparison of cytogenetic and molecular cytogenetic detection of chromosome abnormalities in 240 consecutive adult patients with acute myeloid leukemia. J Clin Oncol 20:2480-2485, 2002 (Pubitemid 34525733)
14. Döhner K, Schlenk RF, Habdank M, et al: Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: Interaction with other gene mutations. Blood 106:3740-3746, 2005 (Pubitemid 41739007)
15. Schlenk RF, Döhner K, Krauter J, et al: Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med 358:1909-1918, 2008 (Pubitemid 351620111)
16. Green CL, Evans CM, Hills RK, et al: The prognostic significance of IDH1 mutations in younger adult patients with acute myeloid leukemia is dependent on FLT3/ITD status. Blood 116:2779-2782, 2010
17. Gale RP, Horowitz MM, Rees JK, et al: Chemotherapy versus transplants for acute myelogenous leukemia in second remission. Leukemia 10:13-19, 1996 (Pubitemid 26052974)
18. Carow CE, Levenstein M, Kaufmann SH, et al: Expression of the hematopoietic growth factor receptor FLT3 (STK-1/Flk2) in human leukemias. Blood 87:1089-1096, 1996 (Pubitemid 26043536)
19. Watson M, Buck G, Wheatley K, et al: Adverse impact of bone marrow transplantation on quality of life in acute myeloid leukaemia patients: Analysis of the UK Medical Research Council AML 10 Trial. Eur J Cancer 40:971-978, 2004 (Pubitemid 38496252)
20. Hann IM, Stevens RF, Goldstone AH, et al: Randomized comparison of DAT versus ADE as induction chemotherapy in children and younger adults with acute myeloid leukemia. Results of the Medical Research Council's 10th AML trial (MRC AML10). Adult and Childhood Leukaemia Working Parties of the Medical Research Council. Blood 89:2311-2318, 1997 (Pubitemid 27143277)
21. Burnett AK, Hills RK, Milligan D, et al: Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: Results of the MRC AML15 trial. J Clin Oncol 29:369-377, 2011
22. Cheson BD, Bennett JM, Kopecky KJ, et al: Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol 21:4642-4649, 2003 (Pubitemid 46594039)
23. Mantel N, Byar DP: Evaluation of responsetime data involving transient states: An illustration using heart-transplant data. J Am Stat Assoc 69:81-86, 1974
24. Mrózek K, Marcucci G, Paschka P, et al: Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: Are we ready for a prognostically prioritized molecular classification? Blood 109:431-448, 2007 (Pubitemid 46105936)
25. Kottaridis PD, Gale RE, Frew ME, et al: The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: Analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood 98:1752-1759, 2001
26. Green CL, Koo KK, Hills RK, et al: Prognostic significance of CEBPA mutations in a large cohort of younger adult patients with acute myeloid leukemia: Impact of double CEBPA mutations and the interaction with FLT3 and NPM1 mutations. J Clin Oncol 28:2739-2747, 2010
27. Preudhomme C, Sagot C, Boissel N, et al: Favorable prognostic significance of CEBPA mutations in patients with de novo acute myeloid leukemia: A study from the Acute Leukemia French Association (ALFA). Blood 100:2717-2723, 2002
28. Marcucci G, Radmacher MD, Maharry K, et al: MicroRNA expression in cytogenetically normal acute myeloid leukemia. N Engl J Med 358:1919-1928, 2008 (Pubitemid 351620112)
29. Paschka P, Marcucci G, Ruppert AS, et al: Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8; 21): A Cancer and Leukemia Group B Study. J Clin Oncol 24:3904-3911, 2006 (Pubitemid 46630738)
30. Ley TJ, Ding L, Walter MJ, et al: DNMT3A mutations in acute myeloid leukemia. N Engl J Med 363:2424-2433, 2010
31. Breems DA, Van Putten WL, Huijgens PC, et al: Prognostic index for adult patients with acute myeloid leukemia in first relapse. J Clin Oncol 23:1969-1978, 2005 (Pubitemid 46211376)